You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康臣葯業(01681.HK)與藥明康德(02359.HK)附屬訂立戰略合作協議及新藥研發項目協議
康臣葯業(01681.HK)公布,全資附屬廣州康臣與藥明康德(02359.HK)直接全資附屬上海藥明於6月27日就研發若干創新藥物的戰略合作訂立戰略合作協議。根據戰略合作協議,雙方擬合作研發主要用於治療腎病及其併發症的創新小分子藥物,並可能隨後擴展至其他疾病領域的其他創新藥物。雙方並將定期討論腎病領域新藥研發上的合作機會,本著共同投資、共同開發、共擔風險的原則,相互將對方列為重要戰略合作夥伴。

另外,廣州康臣與上海藥明於6月28日訂立有關用於急性腎損傷一類新藥研發項目的協議,用於急性腎損傷治療一類新藥研發項目,以急性腎損傷作為首選適應症,由上海藥明負責臨床前的研究開發工作,由廣州康臣向中國藥監局遞交臨床I期試驗申請並獲取臨床默示許可,及負責後續的臨床開發和商業化工作。臨床前候選化合物的知識產權由廣州康臣及上海藥明雙方共同所有,臨床試驗默示許可對應相關的臨床試驗申辦權和生產批件歸廣州康臣獨家所有。

雙方於6月28日亦訂立有關用於尿毒症瘙癢一類新藥研發項目的協議,為用於尿毒症瘙癢治療一類新藥研發項目,以尿毒症瘙癢作為首選適應症,由上海藥明負責臨床前的研究開發工作,由廣州康臣向中國藥監局遞交臨床I期試驗申請並獲取臨床默示許可,及負責後續的臨床開發和商業化工作。臨床前候選化合物的知識產權由廣州康臣及上海藥明雙方共同所有,臨床試驗默示許可對應相關的臨床試驗申辦權和生產批件歸廣州康臣獨家所有。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account